A ims/hypothesis: The extent of coronary atherosclerosis is significantly more advanced in symptomatic type 1 diabetes patients than in symptomatic nondiabetic patients. Whether this difference exists between asymptomatic individuals with diabetes and controls is not documented. In vivo imaging techniques allow quantification of the difference at a preclinical stage.
Introduction
Type 1 diabetes is associated with premature morbidity and mortality. 1, 2 The premature mortality is mostly due to coronary heart disease. 3 When comparing type 1 diabetes patients undergoing coronary angiographic examinations to investigate symptoms of coronary artery disease with nondiabetic controls matched for age and sex, the diabetes population have significantly more stenoses and more frequent three-vessel disease than the controls. 4 Using intravascular ultrasound (IVUS), we demonstrated previously that coronary atherosclerosis is very prevalent in asymptomatic type 1 diabetes patients with no symptoms of coronary artery disease (CAD), and that the degree of atherosclerosis is associ-ated with long-term glycated haemoglobin (HbA 1C ) levels. 5 Subclinical atherosclerosis begins at an early age in the general population. [6] [7] [8] However, no studies have compared the degree of early atherosclerosis in people with type 1 diabetes but no symptoms of CAD with atherosclerosis in nondiabetic controls. The aim of this study was to quantify and compare the degree of coronary atherosclerosis, measured by IVUS, in asymptomatic type 1 diabetes mellitus patients and age-and sex-matched controls.
Subjects, materials and methods

Study population
Twenty-nine patients with type 1 diabetes mellitus and no symptoms of CAD were examined with IVUS. All the patients were part of the Oslo study, in which 45 type 1 diabetes mellitus patients were treated with three different strategies (two injections of insulin daily, multiple insulin injections and insulin pump treatment). The superiority of multiple injections and pump treatment compared to twicedaily insulin was proven in this study. 9 Originally, 45 patients participated in the Oslo study: at 18 years' follow-up, 39 patients were still being followed, four were lost to followup, one had died due to breast cancer and one had died from lung disease. Twenty-nine of these patients volunteered for intracoronary ultrasound examinations, 18 of them male and 11 female. 5 The study protocol was approved by the Regional Ethics Committee. All patients gave written informed consent before they were examined. The examinations of the patients with diabetes took place in 1999 and 2000.
Demographic details and risk factors for cardiovascular disease have been published previously. 5 Of special note, the mean age of the patients was 43 (35-58) years and the mean duration of diabetes was 30 (23-39) years. Mean systolic blood pressure was 129 (+1 SD 16.3) mmHg; mean diastolic blood pressure was 79 (+1 SD 9.0) mmHg. Mean HbA 1C during the 18 years of follow-up was 8.3% (range: 6.6-11.3%).
As controls, we used 29 heart transplant recipients at the Cleveland Clinic Foundation. The donors were age-and sexmatched with the diabetes patients. The mean age of the donors was 43 years (35-58). The epicardial coronaries of healthy donor hearts of 18 males and 11 females served as controls. Based on the international criteria used to accept potential transplant donors, there is reason to assume that this group is representative of the general population. The heart transplantation took place 1+0.2 months prior to the IVUS examination, ensuring that the heart pathology still represents that of the donor. The IVUS examination was part of routine follow-up after transplantation. The comparison of the patients' and the donors' hearts was performed in 2003 using s-VHS videotapes.
IVUS
Cardiac catheterisation was performed with 8F Cyber femoral left and right guide catheters (Boston Scientific, Sunnyvale, CA, USA) from the right side of the groin, using standard Judkins technique. 10 The IVUS system was the Clear View Ultra with Automatic Pullback Device and Ultra Cross 3.2 F -30 MHz catheters (Boston Scientific, USA). A standard dose of intracoronary nitrate (100-200 mcg) was administered before acquisition of images.
The acquisition of IVUS images was very similar for the diabetes patients and the controls, but the pullback length was somewhat shorter in the controls as their examination was limited to mid and proximal segments. The pullback speed for the patients was 1.0 mm/sec and it was 0.5 mm/sec for the controls. The frame rate was 30 frames per second (i.e. each 30th image [pullback speed 1 mm/sec] or each 60th image [pullback speed 0.5 mm/sec] is 1 mm apart). The ultrasound images were recorded on s-VHS videotape for offline analysis. The goal was to examine all three coronary arteries in all patients. The controls were matched to the examined segments. The patients with diabetes were examined in Norway and the videotapes were all examined at The Cleveland Clinic Foundation, Cleveland, USA by the same examiner (TT), using the same method for both diabetes patients and controls.
In accordance with the American College of Cardiology Clinical Expert Consensus Document, 11 we studied the following parameters to measure the degree of atherosclerosis: lumen area (LA), external elastic membrane (EEM) area, plaque area (PA) and plaque thickness (PT). Lumen area is determined by planimetry of the leading edge of the blood- intima acoustic interface, in the normal artery. The EEM was determined by planimetry at the media-adventitia border. Percent area stenosis is the percentage of the EEM area that is occupied by atheroma. 12 
Statistical analysis
When comparing means a two sided t-test was used with 5% significance level. SPSS version 10 (SPSS, Chicago, IL, USA) was used for all statistical analyses.
Results
Twenty-nine patients and 29 age-and sex-matched controls were included in the study. The numbers of images analysed were 3,591 in the diabetic patients and 2,165 in controls. Seventy-six segments were examined for both patients and controls. Mean analysis length was 48.7 mm in patients with diabetes and 29.7 mm in controls. The degree of non-symptomatic coronary atherosclerosis was significantly more severe in individuals with early-onset diabetes mellitus than in controls. This was the case for all variables measured (table 1) . Seventy-six segments (right coronary artery [RCA] =24; left anterior descending artery [LAD] =27; left circumflex artery [LCX] =25) were examined in both patients and controls. The mean percent area stenosis was > 40% in 71% (54/76) of the coronary arteries of the patients, as opposed to 33% (25/76) of the coronary arteries in controls (p<0.0001). The mean maximal plaque thickness was 0.59 mm+ 0.38 mm in patients vs. 0.44 mm+0.30 mm in controls (p<0.0001). The mean minimal plaque thickness was 0.18 mm+0.10 mm vs. 0.12 mm+0.09 mm in controls (p<0.0001).The maximal plaque thickness was > 0.5 mm in 47% of the images studied in the patients and in 30% of the images studied in the controls (p<0.0001).The EEM area was 13.2 mm 2 in diabetes patients vs. 16.2 mm 2 in controls (p<0.0001). Repeat analysis limited to segments with more than 1,200 images in both groups gave similar results (mean percent area stenosis was 32.6+12.4% vs. 23.2+9.1% (p<0.0001), mean maximal plaque thickness was 0.56+0.33 mm vs. 0.41+0.25 mm (p<0.0001) and mean minimal plaque thickness 0.18±0.10 mm vs. 0.11+0.08 mm (p<0.0001), EEM area 14.10+4.93 mm 2 vs. 16.75+5.39 mm 2 (p<0.0001).
Discussion
This study, which measured and quantified subclinical coronary atherosclerosis in type 1 diabetes mellitus with direct measurements (IVUS), clearly demonstrates that people with type 1 diabetes have significantly more advanced subclinical atheromatosis than non-diabetic age-and sex-matched controls. 5, 13 Plaque burden was significantly larger, and the lumen area was smaller, in the diabetic population. The difference in disease severity was demonstrated by the number of coronary artery segments in diabetes patients and controls with greater than 40% area stenosis (71% vs. 33%). The lumen area was also smaller (8.6 vs. 12.1 mm 2 ).
The methods used in this study allowed direct in vivo observation of the inside of coronary arteries with detailed morphology of atherosclerotic lesions. 14 The fact that the same person evaluated all the films using identical methods without any knowledge of the patients strengthens the study. Although the size of the study group is small, the highly statistically significant differences between patients and controls suggest that the results are clinically meaningful.
The epicardial coronaries of healthy donor hearts served as controls. Based on the international criteria used to accept potential transplant donors, there is reason to assume that this group is representative of the general population. The coronary arteries of transplanted hearts are prone to develop post-transplant vasculopathy. However, because the controls were examined within four weeks after transplantation, it is unlikely that transplant vasculopathy would have evolved so quickly.
The longer total length of the coronary artery segment examined in the patients with diabetes may have biased our results. The inclusion of distal segments in the patients would bias the results if disease characteristics were different between proximal, mid and distal segments. However, because both transplant vasculopathy and atherosclerosis are diffuse, systemic disease processes, this is unlikely. We performed additional analyses, in more than 1,200 images in both groups, which provided similar results.
The findings of our study are important because of the high risk of cardiovascular disease and death in type 1 diabetes, 1-3 the reasons for which are not certain. Generally, the majority of myocardial infarctions evolve from mildly stenotic plaques. 15 Many events occur in subjects who do not have prior symptoms of coronary artery disease. Sudden ruptures or erosions of plaque are seen in mildly stenotic and vulnerable plaques. [15] [16] [17] In one angiographic study, coronary incidents, including those leading to coronary occlusion and myocardial infarction, occurred in a majority of patients with stenoses less than 50% and which were not clinically manifest. 18 Normally, compensatory enlargement of coronary arteries accommodates plaque burden during the development of atherosclerosis. 19 The vessel area was, however, smaller in patients than in controls, suggesting negative remodelling in type 1 diabetes mellitus. Negative remodelling may contribute to the development of focal stenoses 20 and might represent a supplementary problem for diabetes patients.
The relative role of the traditional cardiovascular risk factors in type 1 diabetes is incompletely understood. Compared with type 2 diabetes, our patients represent a group which is mainly characterised by long-term hyperglycaemia and fewer metabolic and lipid abnormalities. Hyperglycaemia activates multiple phenomena. 21 Many of these favour the development of atherosclerosis; others play a role in the development of microvascular complications, which can also be risk factors for cardiovascular disease, 22 such as cardiac autonomic neuropathy 23 and albuminuria. 24 Cardiac failure is another documented risk factor for premature death in this patient group. 25 We have previously shown an association between mean long-term glycaemia and coronary artery disease. 5 The present study confirms and quantifies the problem of precocious atherosclerosis in type 1 diabetes, which has also recently been underlined by results from the Diabetes Control and Complications Trial 26, 27 at a preclinical stage.
We believe that our findings, which show a very early involvement of plaque in the coronary vessel walls in type 1 diabetes mellitus patients, should encourage greater attention to prevention and treatment of atherosclerosis in type 1 diabetes at an early stage. 28 Two recent population-based publications showed precocious cardiovascular disease in diabetes, 29, 30 and our findings, like others, 31 suggest moving the focus towards an early identification of preclinical atherosclerosis instead of waiting for symptomatic disease.
